A nice large sample size in this one.
The Lancet- Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study
Vaccine effectiveness of BNT162b2 against infection waned progressively from 92% at day 15-30 to 47% and from day 211 and onwards no effectiveness could be detected. Overall, vaccine effectiveness was lower and waned faster among men and older individuals. The effectiveness waned slightly slower for mRNA-1273, being estimated to 59% from day 181 and onwards. In contrast, effectiveness of ChAdOx1 nCoV-19 was generally lower and waned faster, with no effectiveness detected from day 121 and onwards. whereas effectiveness from heterologous ChAdOx1 nCoV-19 / mRNA was maintained from 121 days and onwards.
Overall, vaccine effectiveness was lower and waned faster among men and older individuals. For the outcome severe Covid-19, effectiveness waned from 89% at day 15-30 to 42% and onwards, with sensitivity analyses showing notable waning among men, older frail individuals, and individuals with comorbidities.

